Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis-Reference-Cited by-同舟云学术

Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis

Published:2023-04 Issue:2 Volume:21 Page:e27-e34
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Hird Amanda E.^ORCID,Dvorani Erind,Saskin Refik,Emmenegger Urban^ORCID,Herschorn Sender,Kodama Ronald,Kulkarni Girish S.,Nam Robert K.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference23 articles.

1. ACS. American Cancer Society: Key Statistics for Prostate Cancer. Accessed January, 2020. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html.

2. Changing incidence of metastatic prostate cancer by race and age, 1988-2015;Dall'Era;Eur Urol Focus,2019

3. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3;Scher;J Clin Oncol,2016

4. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer;Smith;N Engl J Med,2018

5. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer;Hussain;N Engl J Med,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer;Human Vaccines & Immunotherapeutics;2024-08-29

2. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective;Urologic Oncology: Seminars and Original Investigations;2024-06

3. Physician preferences for nonmetastatic castration-resistant prostate cancer treatment in China;Frontiers in Oncology;2024-05-21

4. Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression;Clinical Genitourinary Cancer;2023-09